Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Medicenna Therapeutics Inc.
DescriptionEngineered circularly permuted interleukin-4 (IL-4; BSF1) genetically fused to the catalytic domain of Pseudomonas exotoxin A
Molecular Target Interleukin-4 (IL-4) receptor (CD124) (IL-4RA)
Mechanism of Action 
Therapeutic ModalityBiologic: Fusion protein

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today